secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0000950170-24-106818
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen receives Nasdaq delisting notice over bid price below $1.00
--------------------------------------------------------------------

- Nasdaq notified FibroGen on Sept 12 that its stock closed below $1.00 for 30 consecutive days, triggering potential delisting.
- FibroGen has 180 days, until March 11, 2025, to regain compliance by achieving a closing bid of at least $1.00 for ten consecutive business days.
- If not compliant by March 11, FibroGen may seek an additional 180-day period if it meets other listing requirements and intends to cure, e.g., via reverse stock split.
- FibroGen currently meets all other Nasdaq continued listing standards except the bid price requirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017024106818/0000950170-24-106818-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017024106818/fgen-20240912.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-106818

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer